- About Us
- Media Release
- Our Clients
- Media Mentions
- Subscription Model
- Contact Us
The North America Transdermal Drug Delivery Systems Market would witness market growth of 4.0% CAGR during the forecast period (2022-2028).
The term drug delivery system refers to a group of physicochemical techniques that can regulate the distribution and discharge of pharmacologically active chemicals into cells, tissues, and organs so that they can exert their effects as effectively as possible. DDS, therefore, addresses formulations that effectively administer the medicine to optimize therapeutic efficacy while minimizing any negative effects.
There are many different administration methods, including transdermal administration, oral administration, mucosal administration, lung inhalation, and intravenous injection, depending on the delivery route. The TDDS stands out among them as an appealing strategy. The distribution of numerous therapeutic agents has been greatly impacted by TDDS, particularly in the treatment of disorders of the cardiovascular (CVD) and central nervous systems, hormone therapy, and pain management.
Since TDDS avoids the digestive tract, there is no loss from first-pass metabolism, and medications can be administered without being hampered by pH, enzymes, or intestinal flora. The great persistence of this approach is also attributed to the ability of TDDS to manage medication release in accordance with usage limitations.
The trends of using transdermal drug delivery systems are increasing in North America because of factors including rising demand for non-invasive methods of drug delivery, the growing rate of chronic diseases, and high adoption of self-administration of medications. These factors accompanied by growing investments in R&D for the creation of novel drug delivery systems have made the US the largest market in North America for TDDS. In addition, TDDS is also popularizing in this nation as a result of the presence of numerous producers with strong product portfolios and an increase in product approvals for transdermal medication delivery systems.
The US market dominated the North America Transdermal Drug Delivery Systems Market by Country in 2021; thereby, achieving a market value of $20,370.9 million by 2028. The Canada market is experiencing a CAGR of 6.4% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.4% during (2022 - 2028).
Based on Application, the market is segmented into Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation and Others. Based on Type of Delivery System, the market is segmented into Passive and Active. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris and Hisamitsu Pharmaceutical Co. Inc.
By Type of Delivery System
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.